Search Results - therapeutics+%3e+oncology+%3e+oncology+(small+molecules)

34 Results

Sort By:

Inhibitors of the N-terminal Domain of the Androgen Receptor (UCLA Case No. 2023-075)

Researchers at UCLA under the guidance of Drs. Matthew Rettig and Michael Jung have developed novel molecular compounds that reduce growth of prostate cancer cells. Dr. Jung in collaboration with Dr. Rettig have furthered the development of these compounds by synthesizing a new series of analogues that have similar inhibitory effects. BACKGROUND: Prostate...

Published: 9/23/2024 | Inventor(s): Matthew Rettig, Michael Jung

Keywords(s): androgen receptor therapy, castration resistant prostate cancer, Oncology, Oncology (Small Molecules, Peptides and Antibodies), prostate cancer, small molecules

Category(s): Therapeutics > Oncology, Therapeutics > Oncology > Oncology (Small Molecules)

Temporal Transcriptomic Characterization of Small Cell Neuroendocrine Prostate Cancer (UCLA Case No. 2023-268)

The laboratory of Dr. Thomas Graeber at UCLA developed a novel in vivo model that can characterize mechanisms of the trans-differentiation of prostate cancer into small cell neuroendocrine cancer. BACKGROUND: Prostate cancer is one of the most common cancers among men worldwide, with an estimated 288,300 new cases in the U.S. last year. Among many...

Published: 10/4/2024 | Inventor(s): Thomas Graeber

Keywords(s): neuroendocrine, Oncology, prostate cancer, small cell cancer, transdifferentiation

Category(s): Therapeutics > Oncology > Oncology (Small Molecules), Platforms > Diagnostic Platform Technologies

Antitumor activity of NKTR-214 alone or in combination with anti-PD-1 therapy in tumors resistant to anti-PD-1 (UCLA Case No. 2019-254)

UCLA researchers have discovered a therapy for anti-PD-1 resistant tumors in colon carcinoma patients. A small molecule therapeutic alone or in combination with immune-checkpoint blockade (ICB) therapy exhibits tumor remission even in sublines with mutated signalling pathways that have rendered them ICB resistant. BACKGROUND: Immunotherapy, the...

Published: 2/15/2024 | Inventor(s): Antoni Ribas

Keywords(s): Colon carcinoma, Immune checkpoint blockade, Immunotherapy, Oncology, Oncology (Small Molecules, Peptides and Antibodies), PD-1, PD-L1, Resistant tumors, Signaling pathways, Small molecule therapeutics, Tumor

Category(s): Life Science Research Tools, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology > Oncology (Small Molecules)

2022-301 Multi-Specific Engineered Cytokines

SUMMARY: UCLA researchers in the Department of Bioengineering have developed a novel strategy to engineer multivalent cytokine complexes that significantly increase their selectivity towards activating effector or regulatory immune cells and reduce off-target effects in immunotherapy treatments for cancer and autoimmune diseases. BACKGROUND: In recent...

Published: 9/7/2023 | Inventor(s): Aaron Meyer

Keywords(s):

Category(s): Therapeutics, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology > Oncology (Small Molecules)

2022-106 A Safe, Small Molecule Drug to Prevent Kidney Cancer Metastasis

SUMMARY: UCLA researchers in the Department of Molecular and Medical Pharmacology have discovered a class of small molecule that can be given to kidney cancer patients after surgical removal of their kidney tumor(s) to prevent metastasis and increase their survival rate. BACKGROUND: Kidney cancer is the 10th most common cancer worldwide, accounting...

Published: 7/19/2023 | Inventor(s): Lily Wu

Keywords(s):

Category(s): Therapeutics, Therapeutics > Oncology, Therapeutics > Oncology > Oncology (Small Molecules)

2021-244 MOCETINOSTAT IN COMBINATION WITH CHEMOTHERAPY TO TREAT RHABDOMYOSARCOMA

SUMMARY: Researchers at UCLA’s David Geffen School of Medicine and the UCLA Sarcoma Program have identified a treatment combination which utilizes Mocetinostat in conjunction with chemotherapy for the selective treatment of rhabdomyosarcoma. BACKGROUND: Sarcomas are a heterogeneous group of tumors arising throughout the body’s connective...

Published: 9/5/2023 | Inventor(s): Arun Singh, Noah Federman, Dennis Slamon

Keywords(s):

Category(s): Therapeutics, Therapeutics > Oncology, Therapeutics > Oncology > Oncology (Small Molecules), Therapeutics > Sarcoma And Soft Tissue

2019-523 PROTEIN KINASE INHIBITORS WHICH ALSO TARGET DIHYDROOROTATE DEHYDROGENASE

SUMMARY: Researchers from UCLA’s Department of Molecular and Medicinal Pharmacology have discovered two protein kinase inhibitors that effectively inhibit dihydroorotate dehydrogenase, an enzyme linked to cancer progression. BACKGROUND: During the progression of cancer, normal healthy cells undergo mutation that converts normal cell phenotypes...

Published: 9/5/2023 | Inventor(s): Caius Radu, Evan Abt, Ethan Rosser

Keywords(s):

Category(s): Therapeutics, Therapeutics > Oncology, Therapeutics > Infectious Diseases, Therapeutics > Oncology > Oncology (Small Molecules)

2017-094: Inhibitors of the N-Terminal Domain of the Androgen Receptor

SUMMARYUCLA researchers under the guidance of Drs. Matthew Rettig and Mike Jung have developed a novel family of therapeutics for use against castration resistant prostate cancer. These drugs have been shown to inhibit the androgen receptor and are unaffected by the most common drug-resistant mutations found in prostate cancer patients.BACKGROUNDProstate...

Published: 7/19/2023 | Inventor(s): Matthew Rettig, Michael Jung

Keywords(s):

Category(s): Therapeutics, Therapeutics > Oncology, Therapeutics > Oncology > Oncology (Small Molecules)

2022-086: NANOTECHNOLOGY FOR CHEMOTHERAPY DRUG CAPTURE

SUMMARY: UCLA researchers in the Departments of Chemical Engineering and Bioengineering and Radiological Sciences have developed a cellulose-based nanomaterial for removing excess chemotherapy drugs from the body to reduce the side-effects of cancer therapy. BACKGROUND: Cancer is one of the leading causes of death worldwide, affecting millions of...

Published: 11/15/2024 | Inventor(s): Amir Sheikhi, Ali Khademhosseini

Keywords(s):

Category(s): Materials > Nanotechnology, Therapeutics > Oncology, Therapeutics > Oncology > Oncology (Small Molecules)

2019-610 MONOAMINE OXIDASE BLOCKADE THERAPY FOR TREATING CANCER THROUGH REGULATING ANTITUMOR T CELL IMMUNITY and 2019-611 MONOAMINE OXIDASE BLOCKADE THERAPY FOR TREATING CANCER THROUGH REGULATING TUMOR ASSOCIATED MACROPHAGES (TAMS)

SUMMARY UCLA researchers in the Department of Microbiology, Immunology, and Molecular Genetics identified MAO-A as a drug target and demonstrated repurposing an old antidepressant MAOI for use in combination with cancer immunotherapy methods. BACKGROUND: Monoamine Oxidase A (MAO-A) is a protein of myriad functions relating to neurotransmitter homeostasis...

Published: 11/15/2024 | Inventor(s): Lili Yang

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Oncology > Oncology (Small Molecules)

1 2 3 4